223 related articles for article (PubMed ID: 20211718)
1. Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?
Krautwald M; Münch G
Exp Gerontol; 2010 Oct; 45(10):744-51. PubMed ID: 20211718
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
Srikanth V; Maczurek A; Phan T; Steele M; Westcott B; Juskiw D; Münch G
Neurobiol Aging; 2011 May; 32(5):763-77. PubMed ID: 19464758
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease.
Rahmadi A; Steiner N; Münch G
Clin Chem Lab Med; 2011 Mar; 49(3):385-91. PubMed ID: 21275816
[TBL] [Abstract][Full Text] [Related]
4. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
[TBL] [Abstract][Full Text] [Related]
5. Methylglyoxal, glyoxal, and their detoxification in Alzheimer's disease.
Kuhla B; Lüth HJ; Haferburg D; Boeck K; Arendt T; Münch G
Ann N Y Acad Sci; 2005 Jun; 1043():211-6. PubMed ID: 16037241
[TBL] [Abstract][Full Text] [Related]
6. Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains.
Kuhla B; Boeck K; Schmidt A; Ogunlade V; Arendt T; Münch G; Lüth HJ
Neurobiol Aging; 2007 Jan; 28(1):29-41. PubMed ID: 16427160
[TBL] [Abstract][Full Text] [Related]
7. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains.
Lüth HJ; Ogunlade V; Kuhla B; Kientsch-Engel R; Stahl P; Webster J; Arendt T; Münch G
Cereb Cortex; 2005 Feb; 15(2):211-20. PubMed ID: 15238435
[TBL] [Abstract][Full Text] [Related]
8. Methylglyoxal impairs glucose metabolism and leads to energy depletion in neuronal cells--protection by carbonyl scavengers.
de Arriba SG; Stuchbury G; Yarin J; Burnell J; Loske C; Münch G
Neurobiol Aging; 2007 Jul; 28(7):1044-50. PubMed ID: 16781798
[TBL] [Abstract][Full Text] [Related]
9. Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases.
Grillo MA; Colombatto S
Amino Acids; 2008 Jun; 35(1):29-36. PubMed ID: 18008028
[TBL] [Abstract][Full Text] [Related]
10. Skin beautification with oral non-hydrolized versions of carnosine and carcinine: Effective therapeutic management and cosmetic skincare solutions against oxidative glycation and free-radical production as a causal mechanism of diabetic complications and skin aging.
Babizhayev MA; Deyev AI; Savel'yeva EL; Lankin VZ; Yegorov YE
J Dermatolog Treat; 2012 Oct; 23(5):345-84. PubMed ID: 21756141
[TBL] [Abstract][Full Text] [Related]
11. Immunochemical crossreactivity of antibodies specific for "advanced glycation endproducts" with "advanced lipoxidation endproducts".
Richter T; Münch G; Lüth HJ; Arendt T; Kientsch-Engel R; Stahl P; Fengler D; Kuhla B
Neurobiol Aging; 2005 Apr; 26(4):465-74. PubMed ID: 15653175
[TBL] [Abstract][Full Text] [Related]
12. The model Caenorhabditis elegans in diabetes mellitus and Alzheimer's disease.
Morcos M; Hutter H
J Alzheimers Dis; 2009; 16(4):897-908. PubMed ID: 19387121
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress and aging: is methylglyoxal the hidden enemy?
Desai KM; Chang T; Wang H; Banigesh A; Dhar A; Liu J; Untereiner A; Wu L
Can J Physiol Pharmacol; 2010 Mar; 88(3):273-84. PubMed ID: 20393592
[TBL] [Abstract][Full Text] [Related]
14. epsilon-Glycation, APP and Abeta in ageing and Alzheimer disease: a hypothesis.
Schmitt HP
Med Hypotheses; 2006; 66(5):898-906. PubMed ID: 16442744
[TBL] [Abstract][Full Text] [Related]
15. Methylglyoxal, oxidative stress, and hypertension.
Chang T; Wu L
Can J Physiol Pharmacol; 2006 Dec; 84(12):1229-38. PubMed ID: 17487230
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent changes of glyoxalase I expression in human brain.
Kuhla B; Boeck K; Lüth HJ; Schmidt A; Weigle B; Schmitz M; Ogunlade V; Münch G; Arendt T
Neurobiol Aging; 2006 Jun; 27(6):815-22. PubMed ID: 15950319
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease.
Takeuchi M; Sato T; Takino J; Kobayashi Y; Furuno S; Kikuchi S; Yamagishi S
Med Hypotheses; 2007; 69(6):1358-66. PubMed ID: 17888585
[TBL] [Abstract][Full Text] [Related]
18. Aging induces cardiac diastolic dysfunction, oxidative stress, accumulation of advanced glycation endproducts and protein modification.
Li SY; Du M; Dolence EK; Fang CX; Mayer GE; Ceylan-Isik AF; LaCour KH; Yang X; Wilbert CJ; Sreejayan N; Ren J
Aging Cell; 2005 Apr; 4(2):57-64. PubMed ID: 15771609
[TBL] [Abstract][Full Text] [Related]
19. Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease.
Maczurek A; Shanmugam K; Münch G
Ann N Y Acad Sci; 2008 Apr; 1126():147-51. PubMed ID: 18448809
[TBL] [Abstract][Full Text] [Related]
20. Protein glycation in Saccharomyces cerevisiae. Argpyrimidine formation and methylglyoxal catabolism.
Gomes RA; Sousa Silva M; Vicente Miranda H; Ferreira AE; Cordeiro CA; Freire AP
FEBS J; 2005 Sep; 272(17):4521-31. PubMed ID: 16128820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
